Drug Maker Hit With Securities Suit Over Misstated Study Results
SAN FRANCISCO — A shareholder sued a biopharmaceutical company and its CEO in California federal court on Jan. 23, alleging that the defendants concealed negative clinical trial results for the company’s...To view the full article, register now.
Already a subscriber? Click here to view full article